News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ferring Pharmaceuticals Data Suggest Lower Risk of Cardiovascular Events or Deaths in Prostate Cancer Patients Treated With Degarelix Compared to LHRH Agonists



3/18/2013 10:46:41 AM

SAINT-PREX, Switzerland--(BUSINESS WIRE)--Data presented today at the European Association of Urology (EAU) 2013 annual meeting in Milan, indicate that the gonadotropin releasing hormone (GnRH) antagonist degarelix (brand name: FIRMAGON®) may be associated with lower risk of a cardiovascular (CV) event or death compared to commonly prescribed luteinising hormone-releasing hormone (LHRH) agonists.1 These data are based on a pooled analysis of 2,328 men with prostate cancer from six prospective, randomised trials. Analysis of the data also revealed that the men in the studies treated with FIRMAGON had significantly higher overall survival and improved disease control as evidenced by fewer fractures and a lower incidence of renal or urinary tract adverse events compared to men treated with LHRH agonists.2

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES